WO2001083765A2 - Nucleotides sequences coding for the cdsa gene - Google Patents

Nucleotides sequences coding for the cdsa gene Download PDF

Info

Publication number
WO2001083765A2
WO2001083765A2 PCT/EP2001/003704 EP0103704W WO0183765A2 WO 2001083765 A2 WO2001083765 A2 WO 2001083765A2 EP 0103704 W EP0103704 W EP 0103704W WO 0183765 A2 WO0183765 A2 WO 0183765A2
Authority
WO
WIPO (PCT)
Prior art keywords
gene
codes
polynucleotide
sequence
amino acid
Prior art date
Application number
PCT/EP2001/003704
Other languages
French (fr)
Other versions
WO2001083765A3 (en
Inventor
Madhavan Nampoothiri
Bettina Möckel
Walter Pfefferle
Lothar Eggeling
Hermann Sahm
Original Assignee
Degussa Ag
Forschungszentrum Jülich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Degussa Ag, Forschungszentrum Jülich GmbH filed Critical Degussa Ag
Priority to EP01933786A priority Critical patent/EP1278861A2/en
Priority to KR1020027014698A priority patent/KR20020097245A/en
Priority to AU2001260174A priority patent/AU2001260174A1/en
Publication of WO2001083765A2 publication Critical patent/WO2001083765A2/en
Publication of WO2001083765A3 publication Critical patent/WO2001083765A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241Nucleotidyltransferases (2.7.7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00Preparation of nitrogen-containing organic compounds
    • C12P13/04Alpha- or beta- amino acids
    • C12P13/08Lysine; Diaminopimelic acid; Threonine; Valine

Definitions

  • the present invention provides genetically modified coryneform bacteria, nucleotide sequences coding for phosphatidate cytidylyl transferase and process for the fermentative production of amino acids, in particular L-lysine, using coryneform bacteria, in which the cdsA gene, which codes for phosphatidate cytidylyl transferase, is amplified-.
  • Amino acids in particular L-lysine, are used in human medicine and in the pharmaceuticals industry, but in particular in animal nutrition.
  • strains are obtained which are resistant to antimetabolites, such as for example the lysine analogue S- (2-aminoethyl) cysteine, or are auxotrophic for regulatorily significant amino acids and produce L-amino acids, such as for example L-lysine.
  • antimetabolites such as for example the lysine analogue S- (2-aminoethyl) cysteine, or are auxotrophic for regulatorily significant amino acids and produce L-amino acids, such as for example L-lysine.
  • the object of the present invention was to provide novel auxiliaries for the improved fermentative production of amino acids, in particular L-lysine.
  • This object is achieved by a genetically modified coryneform bacterium, the cdsA gene of which, which codes for phosphatidate cytidylyl transferase, is amplified.
  • Amino acids, in particular L-lysine are used in human medicine, in the pharmaceuticals industry and in particular in animal nutrition. There is accordingly general interest in providing novel improved processes for the production of amino acids, in particular L-lysine.
  • L-lysine or lysine should be taken to mean not only the base, but also salts, such as for example lysine monohydrochloride or lysine sulfate.
  • the present invention provides a genetically modified coryneform bacterium, in which the cdsA gene of which, which codes for phosphatidate cytidylyl transferase, is amplified.
  • amplification describes the increase in the intracellular activity of one or more enzymes in a microorganism, which enzymes are coded by the corresponding DNA. Amplification may be achieved by means of various manipulations of the bacterial cells.
  • Amplification in particular overexpression, may be achieved by increasing the copy number of the corresponding genes, by using a strong promoter or by mutating the promoter and regulation region or the ribosome-binding site located upstream from the structural gene.
  • Expression cassettes incorporated upstream from the structural gene act in the same manner. It is additionally possible to increase expression during fermentative L-lysine production by means of inducible promoters. It is also possible to use a gene which codes for a corresponding enzyme having an elevated activity. Expression is also improved by measures to extend the lifetime of the mRNA. An overall increase in enzyme activity is moreover achieved by preventing degradation of the enzyme. These measures may optionally be combined at will.
  • the microorganisms may produce L-amino acids, in particular L-lysine, from glucose, sucrose, lactose, fructose, maltose, molasses, starch, cellulose or from glycerol and ethanol.
  • the microorganisms may comprise representatives of the coryneform bacteria in particular of the genus Corynebacterium. Within the genus Corynebacterium, the species Corynebacterium glutamicum may in particular be mentioned, which is known in specialist circles for its ability to produce L-amino acids.
  • Suitable strains of the genus Corynebacterium, in particular of the species Corynebacterium glutamicum, are for example the known wild type strains .
  • the present invention also provides an isolated polynucleotide from coryneform bacteria containing a polynucleotide sequence selected from the group
  • polynucleotide which is at least 70% homologous to a polynucleotide which codes for a polypeptide containing the amino acid sequence of SEQ ID no. 2,
  • polynucleotide which codes for a polypeptide which contains an amino acid sequence which is at least 70% homologous to the amino acid sequence of SEQ ID no. 2,
  • polynucleotide containing at least 15 successive nucleotides of the polynucleotide sequence of a) , b) or c) .
  • a polynucleotide sequence is "homologous" to the sequence according to the invention if the base composition and sequence thereof at least 70%, preferably at least 80%, particularly preferably at least 90% matches the sequence according to the invention.
  • a "homologous protein” should be taken to mean proteins which have an amino acid sequence which at least 70%, preferably at least 80%, particularly preferably at least 90% matches the amino acid sequence which is coded by the cdsA gene (SEQ ID no. 1), wherein “matching” should be taken to mean ' that the corresponding amino acids are either identical or comprise mutually homologous amino acids.
  • “Homologous amino acids” are those having corresponding properties, in particular with regard to charge, hydrophobicity, steric properties etc..
  • the present invention moreover provides a polynucleotide as described above, wherein it preferably comprises replicable DNA containing:
  • the present invention also provides
  • polynucleotide replicable in coryneform bacteria, which polynucleotide comprises the nucleotide sequence SEQ ID no. 1, a polynucleotide which codes for a polypeptide which • comprises the amino acid sequence SEQ ID no. 2
  • coryneform bacteria acting as host cell which contain the vector or in which the cdsA gene is amplified.
  • the present invention also provides polynucleotides which contain the complete gene with the polynucleotide sequence according to SEQ ID no. 1 or fragments thereof and which are obtainable by screening by means of hybridization of a suitable gene library with a probe which contains the sequence of the stated polynucleotide according to SEQ ID no. 1 or a fragment thereof and isolation of the stated DNA sequence.
  • Polynucleotide sequences according to . the invention are also suitable as hybridization probes for RNA, cDNA and DNA in order to isolate full length cDNA which code for phosphatidate cytidylyl transferase and to isolate such cDNA or genes, which exhibit a high level of similarity with the sequence of phosphatidate cytidylyl transferase.
  • Polynucleotide sequences according to the invention are furthermore suitable as primers for the polymerase chain reaction (PCR) for the production of DNA which codes for phosphatidate cytidylyl transferase.
  • PCR polymerase chain reaction
  • Such oligonucleotides acting as probes or primers may contain more than 30, preferably up to 30, particularly preferably up to 20, very particularly preferably at least 15 successive nucleotides. Oligonucleotides having a length of at least 40 or 50 nucleotides are also suitable.
  • Polynucleotide generally relates to polyribonucleotides and polydeoxyribonucleotides, wherein the RNA or DNA may be unmodified or modified.
  • Polypeptides are taken to mean peptides or proteins which contain two or more amino acids connected by peptide bonds.
  • polypeptides according to the invention include a polypeptide according to SEQ ID no. 2, in particular those having the biological activity of phosphatidate cytidylyl transferase and also those , which are at least 70%, preferably at least 80%, homologous to the polypeptide according to SEQ ID no. 2 and in particular which exhibit 90% to 95% ho ology to the polypeptide according to SEQ ID no. 2 and exhibit the stated activity.
  • the invention moreover relates to a process for the fermentative production of amino acids, in particular L- lysine, using coryneform bacteria, which in particular already produce an amino acid and in which the nucleotide sequences which code for the cdsA gene are amplified, in particular overexpressed.
  • the present invention presents for the first time the cdsA gene of C. glutamicum which codes for phosphatidate cytidylyl transferase.
  • the cdsA gene or also other genes from C. glutamicum are isolated by initially constructing a gene library of this microorganism in E. coli .
  • the construction of gene libraries is described in generally known textbooks and manuals. Examples which may be mentioned are the textbook by Winnacker: Gene und Klone, Amsterdam Einfiihrung in die Gentechnologie (Verlag Chemie, Weinheim, Germany, 1990) or the manual by Sambrook et al. : Molecular Cloning, A
  • E. coli K-12 strain W3110 which was constructed by Kohara et al. (Cell 50, 495-508 (1987)) in ⁇ -vectors. Bathe et al. (Molecular and General Genetics, 252:255-265, 1996) describe a gene library of C. glutamicum ATCC13032, which was constructed using the cos id vector SuperCos I (Wahl et al., 1987, Proceedings of the National Academy of Sciences USA, 84:2160-2164) in E. coli K-12 strain NM554 (Raleigh et al., 1988, Nucleic Acids Research 16:1563-1575).
  • a gene library of C. glutamicum in E. coli may also be produced using plasmids such as pBR322 (Bolivar, Life Sciences, 25, 807-818 (1979)) or pUC9 (Vieira et al., 1982, Gene, 19:259-268) .
  • Suitable hosts are in particular those E . coli strains with restriction and recombination defects.
  • One example of such a strain is the strain DH5 ⁇ mcr, which has been described by Grant et al.
  • the amino acid sequence of the corresponding protein was furthermore deduced from the above DNA sequence using the methods described above.
  • SEQ ID no. 2 shows the resultant amino acid sequence of the product of the cdsA gene.
  • Coding DNA sequences arising from SEQ ID no. 1 due to the degeneracy of the genetic code are also provided by the present invention. DNA sequences which hybridize with SEQ ID no. 1 or parts of SEQ ID no. 1 are similarly provided by
  • coryneform bacteria produce amino acids, in particular L-lysine, in an improved manner once the cdsA gene has been amplified.
  • genes or gene constructs under consideration may either be present in plasmids in a variable copy number or be integrated into the chromosome and amplified. Alternatively, overexpression of the genes concerned may also be achieved by modifying the composition of the media and culture conditions.
  • the cdsA gene according to the invention was overexpressed with the assistance of plasmids.
  • Suitable plasmids are those which are replicated and expressed in coryneform bacteria.
  • Numerous known plasmid vectors such as for example pZl (Menkel et al., Applied and Environmental Microbiology (1989) 64: 549-554), pEKExl (Eikmanns et al., Gene 102:93-98 (1991)) or pHS2-l (Sonnen et al., Gene 107:69-74 (1991)) are based on the cryptic plasmids pHM1519, pBLl or pGAl .
  • plasmid vectors such as for example those- based on pCG4 (US-A 4,489,160), or pNG2 (Serwold-Davis et al., FEMS Microbiology Letters 66, 119-124 (1990)), or pAGl (US-A 5,158,891) may be used in the same manner.
  • pJClcdsA (Fig. 1), which is based on the E. coli-C. glutamicum shuttle vector pJCl (Cremer et al., 1990, Molecular and General Genetics 220: 478-480) and contains the DNA sequence of C. glutamicum which codes for the cdsA gene. It is contained in the strain DSM5715/pJClcdsA.
  • plasmid vectors are those with the assistance of which gene amplification may be performed by integration into the chromosome, as has for example been described by Reinscheid et al. (Applied and Environmental Microbiology 60, 126-132 (1994)) for the duplication or amplification of the hom-thrB operon.
  • the complete gene is cloned into a plasmid vector which can replicate in a host (typically E. coli ) , but not in C. glutamicum .
  • Vectors which may be considered are, for example, pSUP301 (Simon et al., Bio/Technology 1, 784-791 (1983)), pKl ⁇ mob or pK19mob (Schafer et al., Gene 145, 69- 73 (1994)), pGEM-T (Promega corporation, Madison, I, USA), pCR2.1-TOPO (Shu an (1994). Journal of Biological Chemistry 269:32678-84; US-A 5,487,993), pCR®Blunt (Invitrogen, Groningen, Netherlands; Bernard et al., Journal of
  • the plasmid vector which contains the gene to be amplified is then transferred into the desired strain of C. glutamicum by conjugation or transformation.
  • the conjugation method is described, for example, in Schafer et al. (Applied and Environmental Microbiology 60, 756-759 (1994)). Transformation methods are described, for example, in Thierbach et al. (Applied Microbiology and Biotechnology 29, 356-362 (1988)), Dunican and Shivnan (Bio/Technology 7, 1067-1070 (1989)) and Tauch et al. (FEMS Microbiological Letters 123, 343-347 (1994)). After homologous recombination by means of "crossing over", the resultant strain contains at least two copies of the gene in question.
  • amino acids in particular L-lysine
  • amplify or overexpress not only the cdsA gene, but also one or more enzymes of the particular biosynthetic pathway, of glycolysis, of anaplerotic metabolism, of the citric acid cycle or of amino acid export.
  • amino acids in particular L-lysine
  • amplifying the cdsA gene simultaneously to attenuate
  • essential growth-promoting substances such- as amino acids and vitamins. may also be used in addition to the above- stated substances.
  • Suitable precursors may furthermore be added to the culture medium.
  • the stated feed substances may be added to the culture as a single batch or be fed appropriately during culturing.
  • Basic compounds such as sodium hydroxide, potassium hydroxide, ammonia or ammonia water, or acidic compounds, such as phosphoric acid or sulfuric acid, are used appropriately to control the pH of the culture. Foaming may be controlled by using antifoaming agents such as fatty acid polyglycol esters for example. Plasmid stability may be maintained by the addition to the medium of suitable selectively acting substances, for example antibiotics.
  • Oxygen or oxygen-containing gas mixtures such as air for example, are introduced into the culture in order to maintain aerobic conditions .
  • the temperature of the culture is normally from 20 °C to 45°C and preferably from 25 °C to 40°C.
  • the culture is continued until the maximum quantity of lysine has formed. This objective is normally achieved within 10 hours to 160 hours.
  • L-lysine may be performed by anion exchange chromatography with subsequent ninhydrin derivatization, as described in Spackman et al. (Analytical Chemistry, 30, (1958), 1190).
  • FIG. 1 Map of the plasmid pJClcdsA
  • 0rf2,rep plasmid-coded replication origin, C. glutamicum (from pHM1519)
  • cdsA phosphatidate cytidylyl transferase gene from C. glutamicum ATCC13032
  • Kan kanamycin resistance gene
  • the ligation mixture was then packed in phages using Gigapack II XL Packing Extracts (Stratagene, La Jolla, USA, product description Gigapack II XL Packing Extract, code no. 200217) .
  • E. coli strain NM554 (Raleigh et al. 1988, Nucleic Acid Research 16:1563-1575) was infected by suspending the cells in 10 M MgS0 4 and mixing them with an aliquot of the phage suspension.
  • the cosmid library was infected and titred as described in Sambrook et al.
  • Cosmid DNA from an individual colony was isolated in accordance with the manufacturer's instructions using the Qiaprep Spin Miniprep Kit (Product No. 27106, Qiagen, Hilden, Germany) and partially cleaved with the restriction enzyme Sau3AI (Amersham Pharmacia, Freiburg, Germany, product description Sau3AI, code no. 27-0913-02) .
  • the DNA fragments were dephosphorylated with shrimp alkaline phosphatase (Roche Molecular Biochemicals, Mannheim, Germany, product description SAP, code no. 1758250) .
  • the cosmid fragments of a size of 1500 to 2000 bp were isolated using the QiaExII Gel Extraction Kit (product no.
  • the resultant raw sequence data were then processed using the Staden software package (1986, Nucleic Acids Research, 14:217-231), version 97-0.
  • the individual sequences of the pZero 1 derivatives were assembled into a cohesive contig.
  • Computer-aided coding range analysis was performed using XNIP software (Staden, 1986, Nucleic Acids Research, 14:217-231). Further analysis was performed using the "BLAST search programs" (Altschul et al., 1997, Nucleic Acids Research, 25:3389-3402), against the non-redundant database of the "National Center for Biotechnology Information” (NCBI, Bethesda, MD, USA) .
  • the resultant nucleotide sequence is stated in SEQ ID no. 1.
  • Analysis of the nucleotide sequence revealed an open reading frame of 891 base pairs, which was designated the cdsA gene.
  • the cdsA gene codes for a protein of 297 amino acids .
  • Chromosomal DNA from Corynebacterium glutamicum ATCC 13032 was isolated as described in Tauch et al., (1995, Plasmid 33:168-179) .
  • a DNA fragment bearing the cdsA gene was amplified with the assistance of the polymerase chain reaction. The following primers were used for this purpose:
  • Both oligonucleotides bear the sequence for the cleavage site of the restriction enzyme BamHI (underlined nucleotides) .
  • the stated primers were synthesized by the company MWG Biotech (Ebersberg, Germany) and the PCR reaction was thus performed in accordance with the standard PCR method of Innis et al., (PCR protocol. A guide to methods and applications, 1990, Academic Press).
  • the primers allow the 1095 bp DNA fragment which bears the cdsA gene from Corynebacterium glutamicum to be amplified.
  • the PCR fragment was isolated from the agarose gel using the QiaExII Gel Extraction Kit (product no. 20021, Qiagen, Hilden, Germany) .
  • the PCR fragment obtained in this manner was completely cleaved with the restriction enzyme BamHI.
  • the 1087 bp cdsA fragment was isolated from the agarose gel using the QiaExII Gel Extraction Kit (product no. 1087, Qiagen, Hilden, Germany) .
  • the vector used was the E. coli - C. glutamicum shuttle vector pJCl (Cremer et al., 1990, Molecular and General Genetics 220: 478 - 480).
  • This plasmid was also completely cleaved with the restriction enzyme BamHI and then dephosphorylated with shrimp alkaline phosphatase (Roche Diagnostics GmbH, Mannheim, Germany, product description SAP, product no. 1758250).
  • the cdsA fragment obtained in this manner was mixed with the prepared pJCl vector and the batch was treated with T4 DNA ligase (Amersham Pharmacia, Freiburg, Germany, product description T4 DNA Ligase, code no. 27-0870-04) .
  • the ligation batch was then transformed into E. coli strain DH5 ⁇ (Hanahan, in: DNA cloning. A practical approach. Vol. I. IRL-Press, Oxford, Washington DC, USA). Plasmid-bearing cells were selected by plating the transformation batch out onto LB agar (Lennox, 1995, Virology, 1:190) with 50 mg/1 of kanamycin. After overnight- incubation at 37 °C, individual recombinant clones were selected.
  • Plasmid DNA was isolated from a transformant in accordance with the manufacturer's instructions using the Qiaprep Spin Miniprep Kit (product no. 27106, Qiagen, Hilden, Germany) and cleaved with the restriction enzyme BamHI in order to check the plasmid by subsequent agarose gel electrophoresis .
  • the resultant plasmid was named pJClcdsA.
  • Strain DSM5715 was then transformed with plasmid pJClcdsA using the electroporation method described by Liebl et al. (FEMS Microbiology Letters, 53:299-303 (1989)).
  • Transformant selection proceeded on LBHIS agar consisting of 18.5 g/1 of brain-heart infusion bouillon, 0.5 M sorbitol, 5 g/1 of Bacto tryptone, 2.5 g/1 of Bacto yeast extract, 5 g/1 of NaCl and 18 g/1 of Bacto agar, which had been supplemented with 25 mg/1 of kanamycin. Incubation was performed for 2 days at 33 °C.
  • Plasmid DNA was isolated from a transformant using the conventional methods (Peters-Wendisch et al., 1998,
  • Microbiology 144, 915 - 927
  • the resultant strain was named DSM5717/pJClcdsA and deposited with Deutsche Sammlung fur Mikrorganismen und Zellkulturen (DSMZ, Braunschweig, Germany) in accordance with the Budapest Treaty as DSM 13252.
  • the C. glutamicum strain DSM5715/pJClcdsA obtained in Example 5 was cultured in a nutrient medium suitable for the production of L-lysine and the L-lysine content of the culture supernatant was determined.
  • the strain was initially incubated for 24 hours at 33°C on an agar plate with the appropriate antibiotic (brain/heart agar with kanamycin (50 mg/1) ) .
  • the appropriate antibiotic brain/heart agar with kanamycin (50 mg/1)
  • a preculture was inoculated (10 ml of medium in a 100 ml Erlenmeyer flask) .
  • the complete medium Cglll was used as the medium for this preculture.
  • the pH value was adjusted to pH 7.4.
  • Kanamycin 25 mg/1 was added to this medium.
  • the preculture was incubated for 16 hours at 33 °C on a shaker at 240 rpm.
  • a main culture was inoculated from this preculture, such that the initial OD (660 nm) of the main culture was 0.1.
  • Medium MM was used for the main culture.
  • MOPS morpholinopropanesulfonic 20 g/1 acid
  • CSL, MOPS and the salt solution were adjusted to pH 7 with ammonia water and autoclaved.
  • the sterile substrate and vitamin solutions, together with the dry-autoclaved CaC0 3 are then added.
  • Culturing was performed in a volume of 10 ml in a 100 ml Erlenmeyer flask with flow spoilers. Kanamycin (25 mg/1) was added. Culturing was performed at 33°C and 80% atmospheric humidity. After 48 hours, the OD was determined at a measurement wavelength of 660 nm using a Biomek 1000 (Beckmann Instruments GmbH, Kunststoff) . The quantity of lysine formed was determined using an amino acid analyzer from Eppendorf- BioTronik (Hamburg, Germany) by ion exchange chromatography and post-column derivatization- with ninhydrin detection.
  • Table 1 shows the result of the test.
  • the plasmid pJCcdsA obtained in Example 3 was used to transform C. glutamicum strain ATCC 13032. This strain was transformed as described in Example 4 and checked as in Example 4 by restriction digestion and agarose gel electrophoresis. The strain resultant [sic] ATCC 13032/pJCcdsA was cultured in a nutrient medium suitable for determining growth and growth was determined at various temperatures .
  • the strain was initially incubated for 24 hours at 30 °C as described in Example 5 on an agar plate with the appropriate antibiotic (brain/heart agar with kanamycin (5 mg/1) ) .
  • the appropriate antibiotic brain/heart agar with kanamycin (5 mg/1)
  • a preculture was inoculated (10 ml of medium in a 100 ml Erlenmeyer flask) .
  • the complete medium Cglll stated in Example 5 was used as the medium for this preculture.
  • Kanamycin (25 mg/1) was added to this medium.
  • the preculture was incubated for 16 hours at 30°C on a shaker at 240 rpm.
  • a main culture was inoculated from this preculture, such that the initial OD (600 nm) of the main culture was 0.7.
  • Medium MM was used for the main culture.
  • MOPS morpholinopropanesulfonic 42 g/1 acid
  • Protocatechuic acid 30 mg/1 (sterile-filtered) MOPS and the salt solution were adjusted to pH 7 with ammonia water and autoclaved. The sterile substrate and vitamin solutions were then added.
  • Culturing was performed in a volume of 60 ml in a 500 ml Erlenmeyer flask with flow spoilers. Kanamycin (25 mg/1) was added. Culturing was performed at 40°C. OD was determined at a measurement wavelength of 600 nm using an Ultrospec 3000 (Pharmacia Biotech, Uppsala, Sweden) . Table 2 shows the result of the test.

Abstract

This invention relates to a genetically modified coryneform bacterium, the cdsA gene of which is amplified, and to an isolated polynucleotide, which codes for phosphatidate cytidylyl transferase from coryneform bacteria and to a process for the fermentative production of L-amino acids with amplification of the cdsA gene in the bacteria and to the use of the polynucleotide as a primer or hybridization probe.

Description

Novel nucleotide sequences coding for the cdsA gene
The present invention provides genetically modified coryneform bacteria, nucleotide sequences coding for phosphatidate cytidylyl transferase and process for the fermentative production of amino acids, in particular L-lysine, using coryneform bacteria, in which the cdsA gene, which codes for phosphatidate cytidylyl transferase, is amplified-.
Amino acids, in particular L-lysine, are used in human medicine and in the pharmaceuticals industry, but in particular in animal nutrition.
It is known that amino acids are produced by fermentation of strains of coryneform bacteria, in particular Corynebacterium glutamicum. Due to their great significance, efforts are constantly being made to improve the production process. Improvements to the process may relate to measures concerning fermentation technology, for example stirring and oxygen supply, or to the composition of the nutrient media, such as for example sugar concentration during fermentation, or to working up to yield the product by, for example, ion exchange chromatography, or to the intrinsic performance characteristics of the microorganism itself.
The performance characteristics of these microorganisms are improved using methods of mutagenesis, selection and mutant selection. In this manner, strains are obtained which are resistant to antimetabolites, such as for example the lysine analogue S- (2-aminoethyl) cysteine, or are auxotrophic for regulatorily significant amino acids and produce L-amino acids, such as for example L-lysine.
For some years, methods of recombinant DNA technology have moreover been used to improve strains of Corynebacterium which produce amino acids by amplifying individual biosynthesis genes and investigating the effect on amino acid production. Review articles on this subject may be found inter alia in Kinoshita ("Glutamic Acid Bacteria", in: Biology of Industrial Microorganisms, Demain and Solomon (Eds.), Benjamin Cummings, London, UK, 1985, 115- 142), Hilliger (BioTec 2, 40-44 (1991)), Eggeling (Amino Acids 6:261-272 (1994)), Jetten and Sinskey (Critical Reviews in Biotechnology 15, 73-103 (1995)) and Sahm et al (Annuals of the New York Academy of Science 782, 25-39 (1996)).
The object of the present invention was to provide novel auxiliaries for the improved fermentative production of amino acids, in particular L-lysine.
This object is achieved by a genetically modified coryneform bacterium, the cdsA gene of which, which codes for phosphatidate cytidylyl transferase, is amplified.
Amino acids, in particular L-lysine, are used in human medicine, in the pharmaceuticals industry and in particular in animal nutrition. There is accordingly general interest in providing novel improved processes for the production of amino acids, in particular L-lysine.
Any subsequent mention of L-lysine or lysine should be taken to mean not only the base, but also salts, such as for example lysine monohydrochloride or lysine sulfate.
The present invention provides a genetically modified coryneform bacterium, in which the cdsA gene of which, which codes for phosphatidate cytidylyl transferase, is amplified.
In this connection, the term "amplification" describes the increase in the intracellular activity of one or more enzymes in a microorganism, which enzymes are coded by the corresponding DNA. Amplification may be achieved by means of various manipulations of the bacterial cells.
Amplification, in particular overexpression, may be achieved by increasing the copy number of the corresponding genes, by using a strong promoter or by mutating the promoter and regulation region or the ribosome-binding site located upstream from the structural gene. Expression cassettes incorporated upstream from the structural gene act in the same manner. It is additionally possible to increase expression during fermentative L-lysine production by means of inducible promoters. It is also possible to use a gene which codes for a corresponding enzyme having an elevated activity. Expression is also improved by measures to extend the lifetime of the mRNA. An overall increase in enzyme activity is moreover achieved by preventing degradation of the enzyme. These measures may optionally be combined at will.
The microorganisms, provided by the present invention, may produce L-amino acids, in particular L-lysine, from glucose, sucrose, lactose, fructose, maltose, molasses, starch, cellulose or from glycerol and ethanol. The microorganisms may comprise representatives of the coryneform bacteria in particular of the genus Corynebacterium. Within the genus Corynebacterium, the species Corynebacterium glutamicum may in particular be mentioned, which is known in specialist circles for its ability to produce L-amino acids.
Suitable strains of the genus Corynebacterium, in particular of the species Corynebacterium glutamicum, are for example the known wild type strains .
Corynebacterium glutamicum ATCC13032 Corynebacterium acetoglutamicum ATCC15806 Corynebacterium acetoacidophilum ATCC13870 Corynebacterium thermoaminogenes FERM BP-1539 Corynebacterium melassec.ola ATCC17965 Brevibacteriu flavum ATCC14067 Brevibacterium lactofermentum ATCC13869 and
Brevibacterium divaricatum ATCC14020
and L-lysine producing mutants or strains produced therefrom, such as for example
Corynebacterium glutamicum FERM-P 1709 Brevibacterium flavum FERM-P 1708
Brevibacterium lactofermentum FERM-P 1712 Corynebacterium glutamicum FERM-P 6463 Corynebacterium glutamicum FERM-P 6464 and Corynebacterium glutamicum DSM5715.
The present invention also provides an isolated polynucleotide from coryneform bacteria containing a polynucleotide sequence selected from the group
a) polynucleotide which is at least 70% homologous to a polynucleotide which codes for a polypeptide containing the amino acid sequence of SEQ ID no. 2,
b) polynucleotide which codes for a polypeptide which contains an amino acid sequence which is at least 70% homologous to the amino acid sequence of SEQ ID no. 2,
c) polynucleotide which is complementary to the polynucleotides of a) or b) , and
d) polynucleotide containing at least 15 successive nucleotides of the polynucleotide sequence of a) , b) or c) .
For the purposes of the present application, a polynucleotide sequence is "homologous" to the sequence according to the invention if the base composition and sequence thereof at least 70%, preferably at least 80%, particularly preferably at least 90% matches the sequence according to the invention. According to the present invention, a "homologous protein" should be taken to mean proteins which have an amino acid sequence which at least 70%, preferably at least 80%, particularly preferably at least 90% matches the amino acid sequence which is coded by the cdsA gene (SEQ ID no. 1), wherein "matching" should be taken to mean' that the corresponding amino acids are either identical or comprise mutually homologous amino acids. "Homologous amino acids" are those having corresponding properties, in particular with regard to charge, hydrophobicity, steric properties etc..
The present invention moreover provides a polynucleotide as described above, wherein it preferably comprises replicable DNA containing:
(i) the nucleotide sequence shown in SEQ ID no. 1, or
(ii) at least one sequence which corresponds to the sequence (i) within the degeneration range of the genetic code, or
(iii) at least one sequence which hybridizes with the complementary sequence to sequence (i) or (ii) and optionally
(iv) functionally neutral mutations in (i) which give rise to the same or a homologous amino acid.
The present invention also provides
a preferably recombinant polynucleotide replicable in coryneform bacteria, which polynucleotide comprises the nucleotide sequence SEQ ID no. 1, a polynucleotide which codes for a polypeptide which comprises the amino acid sequence SEQ ID no. 2
a vector containing the DNA sequence of C. glutamicum which codes for the cdsA gene, contained in the' vector pJClcdsA, deposited in Corynebacterium glutamicum under the number 13252,
and coryneform bacteria acting as host cell which contain the vector or in which the cdsA gene is amplified.
The present invention also provides polynucleotides which contain the complete gene with the polynucleotide sequence according to SEQ ID no. 1 or fragments thereof and which are obtainable by screening by means of hybridization of a suitable gene library with a probe which contains the sequence of the stated polynucleotide according to SEQ ID no. 1 or a fragment thereof and isolation of the stated DNA sequence.
Polynucleotide sequences according to . the invention are also suitable as hybridization probes for RNA, cDNA and DNA in order to isolate full length cDNA which code for phosphatidate cytidylyl transferase and to isolate such cDNA or genes, which exhibit a high level of similarity with the sequence of phosphatidate cytidylyl transferase.
Polynucleotide sequences according to the invention are furthermore suitable as primers for the polymerase chain reaction (PCR) for the production of DNA which codes for phosphatidate cytidylyl transferase.
Such oligonucleotides acting as probes or primers may contain more than 30, preferably up to 30, particularly preferably up to 20, very particularly preferably at least 15 successive nucleotides. Oligonucleotides having a length of at least 40 or 50 nucleotides are also suitable.
"Isolated" means separated from its natural environment. "Polynucleotide" generally relates to polyribonucleotides and polydeoxyribonucleotides, wherein the RNA or DNA may be unmodified or modified.
"Polypeptides" are taken to mean peptides or proteins which contain two or more amino acids connected by peptide bonds.
The polypeptides according to the invention include a polypeptide according to SEQ ID no. 2, in particular those having the biological activity of phosphatidate cytidylyl transferase and also those , which are at least 70%, preferably at least 80%, homologous to the polypeptide according to SEQ ID no. 2 and in particular which exhibit 90% to 95% ho ology to the polypeptide according to SEQ ID no. 2 and exhibit the stated activity.
The invention moreover relates to a process for the fermentative production of amino acids, in particular L- lysine, using coryneform bacteria, which in particular already produce an amino acid and in which the nucleotide sequences which code for the cdsA gene are amplified, in particular overexpressed.
The present invention presents for the first time the cdsA gene of C. glutamicum which codes for phosphatidate cytidylyl transferase.
The cdsA gene or also other genes from C. glutamicum are isolated by initially constructing a gene library of this microorganism in E. coli . The construction of gene libraries is described in generally known textbooks and manuals. Examples which may be mentioned are the textbook by Winnacker: Gene und Klone, Eine Einfiihrung in die Gentechnologie (Verlag Chemie, Weinheim, Germany, 1990) or the manual by Sambrook et al. : Molecular Cloning, A
Laboratory Manual (Cold Spring Harbor Laboratory Press, 1989) . One very well known gene library is that of E. coli K-12 strain W3110, which was constructed by Kohara et al. (Cell 50, 495-508 (1987)) in λ-vectors. Bathe et al. (Molecular and General Genetics, 252:255-265, 1996) describe a gene library of C. glutamicum ATCC13032, which was constructed using the cos id vector SuperCos I (Wahl et al., 1987, Proceedings of the National Academy of Sciences USA, 84:2160-2164) in E. coli K-12 strain NM554 (Raleigh et al., 1988, Nucleic Acids Research 16:1563-1575). Bόrmann et al. (Molecular Microbiology 6(3), 317-326, 1992)) also describe a gene library of C. glutamicum ATCC13032, using cosmid pHC79 (Hohn and Collins, Gene 11, 291-298 (1980)). A gene library of C. glutamicum in E. coli may also be produced using plasmids such as pBR322 (Bolivar, Life Sciences, 25, 807-818 (1979)) or pUC9 (Vieira et al., 1982, Gene, 19:259-268) . Suitable hosts are in particular those E . coli strains with restriction and recombination defects. One example of such a strain is the strain DH5αmcr, which has been described by Grant et al. (Proceedings of the National Academy of Sciences USA, 87 (1990) 4645-4649) . The long DNA fragments cloned with the assistance of cosmids may then in turn be sub-cloned in usual vectors suitable for sequencing and then be sequenced, as described, for example, in Sanger et al. (Proceedings of the National Academy of Sciences of the United States of America, 74:5463-5467, 1977).
The novel DNA sequence from C. glutamicum which codes for the cdsA gene and, as SEQ ID no. 1, is provided by the present invention, was obtained in this manner. The amino acid sequence of the corresponding protein was furthermore deduced from the above DNA sequence using the methods described above. SEQ ID no. 2 shows the resultant amino acid sequence of the product of the cdsA gene.
Coding DNA sequences arising from SEQ ID no. 1 due to the degeneracy of the genetic code are also provided by the present invention. DNA sequences which hybridize with SEQ ID no. 1 or parts of SEQ ID no. 1 are similarly provided by
Figure imgf000010_0001
Ό CU Cfl CO O O !£ (D P- H (-» CΛ Λ l-i ^ ω α (D SD O (D o SD H- rt Cfl Ω SD Hi Co SD TJ rt hi h-1 Φ K H Φ " H J π c M Φ H- m 3 I-1 l-J Hi CD I-1 - h-1 3 zr tr hi β TJ K tr
(D P- rP. P- H σ P- Φ Φ Ω IO SD 3 ιO Dy CO H- H- • 53 • Hi Φ tr (D φ 3 Φ SD 0 φ
Ω U β CΛ 3 H (D 3 3 ^ Ω SD O CO KQ O φ o H ω 3 α Ω 3 rt ft φ ^ (D P- rt TJ d H rt I-1 H to H- Φ "^ iQ . ^ l-i φ rt ιQ Hi (D H- H- Φ P-
P- P- 3 Φ CO 3 P- P- Φ Ω O o H- t-1 σ Φ TJ 3 3 m TJ (D 3 O SD Φ β 3 fl) 3 P- 3
Ω 3 Ω α rt • P- 3 H H t-1 O ^ Λ H ιQ Φ Φ H 3 o SD Hi 3 O 3 Φ \~- φ 3 < o> Φ Φ ^ N >< Cfl Φ H- 3 3 3 c O rt Ω 0 c rt • rt Ω 3 H- φ rt Cfl μ- 3 SD rt P- O O ιQ O O φ <j H- H- r rf Φ hi H- H- r+ rt rt O O ^ 3 ° 3 (D t-1 rt 3* 3 3 rt O ^-, CJ • 3 H- 3 Ω 3 Φ rt 3 O H3 SD O H- (D rt l-J rt
(D Φ β rt to P- Φ ιQ H- 3 TJ s Ω Cfl O H- SD 3 r (-' O l-1 Hi P-
TJ Cfl rt P- υD 0 Cfl α C i-1 o > Φ Φ (D 3 SD (-• φ rt 3 Ω 0 O O
T 3 P- 3" Ω 3 3 σ ? φ Ω 2 O α (D O 1— H- ^ tr SD Ω H- Hi H 3
H SD 3 φ — (D s H- Cfl (D fl (D Ω 3 iQ ω • 0 3 TJ φ I-1 tr hi • o 3 iQ CO 3 t-1 • Φ H Φ H t. σ 0 0- ^< Ω Hi Φ H- (D Ω SD Φ
J-υ £ SD SD (D Hi β H1 O φ c & Φ tr • l-i H- . — . rr i 3 2 •< 3 (-1 CO O
Ω SD rt hj Ω 3 hj SD fl φ rt CO c H- H 3 cn Φ cn Dd t fl TJ ιQ Φ TJ SD 0 r I-1 3" rt rr α O Φ Q- W- SD H- Φ CO Ω rt Φ O • • 3 φ (D H- O (D (D 3 Φ CO SD 3 3
Φ Φ 3 Λ H1 3 3 H- if r Cfl I-1 H-1 Ω 3 Ω O 3 H- 3 φ hi TJ CΛ
^-» σ 3 hi P- β H- Φ O ιQ Ω 3 Φ TJ φ GO Φ Φ rt j β H- SD rt Φ
H • TJ SD P- 3 eα Hi Φ 3 O O Φ H- 31 0 Ω IV) Cfl Φ Ω fl \ rt 3 CO P- Φ H 0 0 0 O 1 3 O CO t-1 *≤. TJ 3 C H1 -J H 0 ? O o hi Ω <l f Q t→ φ Φ Ω rt rt TJ I-1 (D rj- H 1 ω ~J H- 3 H- hi hi SD SD rt SD
SD ι Hi O P- 31 Φ 3^ *< l-i H- TJ H H Φ H- (D H-> '• o 3 h-1 Ω CO SD tr rt
TJ P- 3 P- ιQ Φ H O fl Φ TJ O U3 H H H- CO 3 hi ) N3 IV) Φ h-1 3 o • rt Φ Ω Φ p- l-i rt Φ 3 ^< tr P- H H- <! O 0 ^ α Φ ι£ NJ ω o Ω φ SD H- 3 P- <J
Φ • • α J 3 Q σ (D Ω H- 3 o. H- 3 tr (Jl o ιQ rt ^ rt H <! O CO Φ en u — . iQ << SD C c TJ N rt 3 H- 1 1 H- Φ rt H- φ β
* e*n O O P- P> φ Φ CΛ rt I-' Φ Ω Ω H Φ (D O . — , tv> IV) O H- Φ H rt Hi σ fl
I-1 φ 3 UD rt H • 3 h-1 α h-1 Φ O H- 3 h-1 -1 !te» on h-1 3 3 <! 3 H- ^ 3 o CΛ β
P- O l£> Cfl φ 3 *< Φ α 5: 3 3 O to -J f-> cπ Φ H- co β l-J rt σ
O a Ω rt (D 3 rt (D (D cr O H- μ- <! Φ iQ H- rt 3 3 0 rt P- O
X O " H I-1 SD Φ 3 ^ " ^< rt σ rt Φ H . — . ^~.
^ 3 tr C Hi Hi (D KΩ rt rt t-h 3 SD β • 3 3 (D H- r ϊϊ rt < o 3 h-1 rt φ Cfl O β rt β P-
O β P- Ω Ji. 3 Hi <i rt Hi i£> D cπ Φ rt H rt H- β rt rt l-i Ω 3 rt 3" G o H- φ * Φ rt O H- l-i fe1 Ω h-1 H (D (D O rt tr O rt P- β
Q. f-> H- H Φ O Hi 3 Φ 3^ tr M O 0 3 SD J^ 1 hi σ Hi tr Φ 3 SD O rt-
^ Φ l-i O 3 P- φ (D TJ φ 3 3 H- 3 • — -J (D rt H- Φ ω 3 3 P-
O Φ 3 M rt 3 H 3J TJ H • 3 α — - Cπ h-1 SD l-J TJ P- O σ rt (D O Cn Φ CO H- H h H- TJ rt H CΛ O *« **. ~J H- ≤ H- 3 H *. Ω O 3 π P- Ω Cπ H O σ 3 Φ Φ 3 O t σ M H- (D H- N TJ O 0 Hi CΛ α rt Hi 1 3 3 O H Cfl 3 CO Φ \-> Φ lO (D 3 H- H- . — . H Φ H hi rt s: SD
Φ P- 0 IV) SD σ β H- rt iQ φ H ι< 3 Ω 3 3 H- -1 O Φ Φ tr Ω ιQ O
O 1-1 C? rt tπ P- ι-( rt 3 Cfl 3 H- 0 H H- w UD 3 rt rt H- H- P- h-1 Hi
<£> fl 3 O P-' α H- C 3J rt φ 3 • σ 3 ffi CΛ Hi zr Φ ?r 3 Ω <
00 SD "— ' O Φ N Ω 0 n <! O O (D CO H- Φ H- 3 -> tr "^ Ω SD
>C- - 3 ,— . U • 3 K (D rt O H- σ SD Φ 3 CO s: Ω tr - — φ 3 3 0 P-
— 3 rt TJ TJ SD (D Hi rt H- Hi 3 rt CO 3 O Φ 3 ^r H- — ' 3 & Hi £ H- hi SD 3 P-
"zr o ι-3 3 O P- O <! (D φ rt O • Λ c 3 -> 1 £ α 3 • φ l-J Φ 3
SD Φ 50 P- zr 3 l-i O 3 SD Φ H- H- H f- rt h-1 1 to 3 O Φ O φ O
3 ω — l-ti φ -i •P1 3 CO rt 3 3 Ω O ro φ Φ H- ι-3 H- SD Ω rt β Hi
P- P- ^ 0 Φ rt Φ 31 3 T 3 X O 3 Cfl rt 3 tr -1
• ?r O SD co P- P- TJ β P- P- H- Hi h-1 H- (D SD (D Ω rt φ rr CO H- O ID rt rt 3 h Ω
P- • • 3 3 φ j 3% 3 O Φ 0 H- l-i H Φ tr rt W (D O rt rt - o P-
3 rt H 3 * rt rt H (D 3 Hi 3 rt Φ Cfl O rt 3 Φ H-
SD Φ fl (D φ Φ ω * H Cfl 0 (D Φ 3 3 fl
D O l-i H rt 0 H rt φ
3 3 0 Cfl rt 3 P- P-
Hi O 3 3
Newton & Graham, PCR (Spektrum Akademischer Verlag, Heidelberg, Germany, 1994) .
During work on the present invention, it proved possible to establish that coryneform bacteria produce amino acids, in particular L-lysine, in an improved manner once the cdsA gene has been amplified.
The genes or gene constructs under consideration may either be present in plasmids in a variable copy number or be integrated into the chromosome and amplified. Alternatively, overexpression of the genes concerned may also be achieved by modifying the composition of the media and culture conditions.
The person skilled in the art will find guidance in this connection inter alia in Martin et al. (Bio/Technology 5, 137-146 (1987)), in Guerrero et al. (Gene 138, 35-41
(1994)), Tsuchiya and Morinaga (Bio/Technology 6, 428-430 (1988)), in Eikmanns et al. (Gene 102, 93-98 (1991)), in European patent EPS 0 472 869, in US patent 4,601,893, in Schwarzer and Pϋhler (Bio/Technology 9, 84-87 (1991) [sic] , in Reinscheid et al. (Applied and Environmental
Microbiology 60, 126-132 (1994)), in LaBarre et al. (Journal of Bacteriology 175, 1001-1007 (1993)), in patent application WO 96/15246, in Malumbres et al. (Gene 134, 15- 24 (1993)), in Japanese published patent application JP-A- 10-229891, in Jensen and Hammer (Biotechnology and Bioengineering 58, 191-195 (1998)), in Makrides (Microbiological Reviews 60:512-538 (1996)) and in known textbooks of genetics and molecular biology.
By way of example, the cdsA gene according to the invention was overexpressed with the assistance of plasmids.
Suitable plasmids are those which are replicated and expressed in coryneform bacteria. Numerous known plasmid vectors, such as for example pZl (Menkel et al., Applied and Environmental Microbiology (1989) 64: 549-554), pEKExl (Eikmanns et al., Gene 102:93-98 (1991)) or pHS2-l (Sonnen et al., Gene 107:69-74 (1991)) are based on the cryptic plasmids pHM1519, pBLl or pGAl . Other plasmid vectors, such as for example those- based on pCG4 (US-A 4,489,160), or pNG2 (Serwold-Davis et al., FEMS Microbiology Letters 66, 119-124 (1990)), or pAGl (US-A 5,158,891) may be used in the same manner.
One example of a plasmid by means of which the cdsA gene may be overexpressed is pJClcdsA (Fig. 1), which is based on the E. coli-C. glutamicum shuttle vector pJCl (Cremer et al., 1990, Molecular and General Genetics 220: 478-480) and contains the DNA sequence of C. glutamicum which codes for the cdsA gene. It is contained in the strain DSM5715/pJClcdsA.
Further suitable plasmid vectors are those with the assistance of which gene amplification may be performed by integration into the chromosome, as has for example been described by Reinscheid et al. (Applied and Environmental Microbiology 60, 126-132 (1994)) for the duplication or amplification of the hom-thrB operon. In this method, the complete gene is cloned into a plasmid vector which can replicate in a host (typically E. coli ) , but not in C. glutamicum . Vectors which may be considered are, for example, pSUP301 (Simon et al., Bio/Technology 1, 784-791 (1983)), pKlδmob or pK19mob (Schafer et al., Gene 145, 69- 73 (1994)), pGEM-T (Promega corporation, Madison, I, USA), pCR2.1-TOPO (Shu an (1994). Journal of Biological Chemistry 269:32678-84; US-A 5,487,993), pCR®Blunt (Invitrogen, Groningen, Netherlands; Bernard et al., Journal of
Molecular Biology, 234: 534-541 (1993)) or pEMl (Schrumpf et al, 1991, Journal of Bacteriology 173:4510-4516). The plasmid vector which contains the gene to be amplified is then transferred into the desired strain of C. glutamicum by conjugation or transformation. The conjugation method is described, for example, in Schafer et al. (Applied and Environmental Microbiology 60, 756-759 (1994)). Transformation methods are described, for example, in Thierbach et al. (Applied Microbiology and Biotechnology 29, 356-362 (1988)), Dunican and Shivnan (Bio/Technology 7, 1067-1070 (1989)) and Tauch et al. (FEMS Microbiological Letters 123, 343-347 (1994)). After homologous recombination by means of "crossing over", the resultant strain contains at least two copies of the gene in question.
It may additionally be advantageous for the production of amino acids, in particular L-lysine, to amplify or overexpress not only the cdsA gene, but also one or more enzymes of the particular biosynthetic pathway, of glycolysis, of anaplerotic metabolism, of the citric acid cycle or of amino acid export.
For the production of L-lysine, for example, it is thus possible simultaneously to amplify, in particular overexpress or amplify [sic] , one or more genes selected from the group
• the dapA gene which codes for dihydropicolinate synthase (EP-B 0 197 335) , or
• the dapE gene which codes for succinyldiaminopimelate desuccinylase, or
• the lysC gene which codes for a feed back resistant aspartate kinase (Kalinowski et al. (1990), Molecular and General Genetics 224, 317-324), or
• the gap gene which codes for glyceraldehyde-3-phosphate dehydrogenase (Eikmanns (1992) , Journal of Bacteriology 174:6076-6086), or • the tpi gene which codes for triosephosphate isomerase (Eik anns (1992), Journal of Bacteriology 174:6076-6086), or
• the pgk gene which codes for 3-phosphoglycerate kinase (Eikmanns (1992), Journal of Bacteriology 174:6076-6086), or
• the pyc gene which codes for pyruvate carboxylase (DE-A- 19831609), or
• the mqo gene which codes for malate: quinone oxidoreductase (Molenaar et al., European Journal of Biochemistry 254, 395-403 (1998)), or
• the lysE gene which codes for lysine export (DE-A-195 48 222)
It may furthermore be advantageous for the production of amino acids, in particular L-lysine, in addition to amplifying the cdsA gene, simultaneously to attenuate
• the pck gene which codes for phosphoenolpyruvate carboxykinase (DE 199 50 409.1, DSM 13047) and/or
• the pgi gene which codes for glucose 6-phosphate isomerase (US 09/396,478, DSM 12969) and/or
• the poxB gene which codes for pyruvate oxidase (DE.-1995 1975.7) .
It may furthermore be advantageous for the production of amino acids, in particular L-lysine, in addition to overexpressing the cdsA gene, to suppress unwanted secondary reactions (Nakayama: "Breeding of Amino Acid Producing Microorganisms", in: Overproduction of Microbial Products, Krumphanzl, Sikyta, Vanek (eds.), Academic Press, London, UK, 1982) . w cπ o cπ o cπ
Ω Ω α TJ SD 3 SD Ω Ω (D β P- (D SD SD Φ CO CO KQ s: O Hi <1 hi m S! TJ co 3 hi β P- tr1 •I o 0 P- tr O P- 3 0 0 CO Cfl 3 Ω 3 3 X 0 rt H tr SD O SD φ tr P- φ P- O φ Φ Cfl >-> 1 0
3 3 TJ o rt § 3 H φ α P- α SD ^ (D β p- Ω hi H & Φ φ H Ω o P- rt TJ P- < ^ i rt rt o Cfl (D H O T 3 TJ P- 3 SD hi Ω Ω rt P- β P- P» <! o tr Φ 3 φ
(D (D rt TJ (D 3 0 φ <i Φ TJ Ω o tr Φ Q 0 P- Ω r TJ — φ TJ 0 SD ιQ 3 O rt
P- P- (D tr 3 rt P- β CO TJ Ω P- Hi rt P- 0 tr CO hi Φ β H β (D tr — hj hi rt rt μ- tr
3 3 CO 0 P- Φ β 3 rt rt 0 0 3" 3 Φ μ- Φ 3 P- 3 Cfl φ α Φ Hi o CΛ Φ rt P- 3 Φ
P- Cfl H X • 3 α Φ O 3 β H SD 0 "•« PJ 0) SD o Φ 3 rt Φ H o SD N tr O φ
3 3 P- P- rt CO Φ 3 TJ SD 3 P1 3 H hi 3 φ β 3 Φ H tr φ P- φ 3 TJ
Φ ιQ β Ω β m TJ ^ TJ Φ hi H Φ 0 Φ Hi CO 0 SD P- 3 H ^» hi O O H, β rt 3 hf tr tr Cfl P- X h-1 P- SD CO β σ vQ P1 Ω rt φ M P- φ CO φ σ 3 rt H
SD CΛ SD φ Φ 0 CO ^ ^ CΛ •< SD Ω rt β Ω Ω Φ " hi CO P- 3 3 rt LQ α SD SD tr TJ -1 o tr Ω • CO β P- Φ 3 Hi rt 3 Φ hi CO O 3 ) 3 CΛ φ P- rt *< Φ 0 ι< P- 3 TJ Ω Λ < 0 TJ 0 SD *< Hi P' O β -—^ SD O O φ < ) H rt rt Ω cr Ω Cfl
CO P- a. o. TJ P- tr tr β Φ O H hi Ω r-1 P1 CO CO s! Ω H Hi α *- P- tr φ tr φ SD 3* cr 3 φ
SD β H ^ tr rt SD O (D hi Φ P- SD 0 β Φ φ SD rt Q P- — - Ω φ Ω 3 3 rt Φ μ- CO r-> 3 o o hi rt ID H O ιQ (D • Φ α Ω £ H •^ 0- CO Φ SD rt β tr tr P- Ω TJ Ω rt KQ TJ CO O φ CO "* rt (D O X P- Φ o tr 3 tr 3 • rt rt 3 ? P- tr j Ω hi 0 n Φ o TJ ιQ ^ 3 SD Hi H CO h-1 SD P- P- P- φ β Φ P- 3 O β O Hi m 3 rt tr Φ SD CO Φ P- SD P. o CO Φ SD hi 3 O CO rt 3 X ? TJ Ω O tr (D o 3 (D 3 O X Ω tr TJ H o Ω Φ iQ h-1 3 TJ O ιQ rt rt H Φ rt hi SD
Cfl Φ TJ CO H 3 § •<: rt 3 Φ P- Hi rt rt O O SD Φ r , — , tr O CO β ιQ 3 β t CO β CO § o SD H Ω P- Φ Φ CO -1 o O CO O iQ l-J cr 3 o Q H Φ Ω Cfl l-J SD μ-
Ω Ω o P- CΛ O o 3 (D O X Φ ** β hi CO β 3 t< SD rt Φ o β P- Φ Φ 3 3 tr β ω β β 3 μ- Hi Ω 3 rt SD Ω Φ IT) H P- , — . r CΛ 3 rt CO O P- O
TJ 3 CO hi P- β P" rt TJ β CO SD 3 tr TJ Φ ** SD O Φ Ω β < rt Hi Φ O l-J CO α> rt o Ω β 3 O •» 0 hi β 3 TJ φ X hi Hi β Cfl P- σ SD β: X • Ω 3 SD
CΛ β SD β Φ 3 β β φ σ α * SD SD SD Hi CO O hi α Φ φ •<: < tr rt rt o Cfl Ω hi rt P- hi CO O hi 3 3 φ CO 3 3 H O Φ SD £ l-J cr > tr 3 μ-
Hi φ φ tr Ω Ω β φ α rt o *% β TJ β (D ^ 3 CO H Φ O " β O φ rt TJ α o > Φ 3 (D h-1 SD (D O 2 (D H TJ rt P' Ω 3 Ω 3 ιQ rt P- 3 O CΛ P- hi l-J 3 o Cfl (D H Hi 3 rt P- 3 iQ SD SD φ rt σ rt h{ O β o CA ιQ ? β Hi 3 0 TJ
Φ hi j <: σ SD o_ Ω rt Ω . SD P-< o O Λ tr P- rt Cfl < hi Ω 3 φ β H φ o £ o rt Φ O j Φ 3 Ω 3 μ- Cfl Ω > Φ cr hi rt Φ tr tr P- cr 3 α o β 0
X P- rt ιQ tr σ 3 Φ X 3 0 CO P- o P- P" 0 φ SD Φ SD H SD φ 3 •< SD β Ω α
(D β tr Φ P- Φ (D ^ hi rt rt ιQ Ω tr rt P- *% hi α P- SD H fl hi hi cr CO φ
3 3 φ 3 Ω r Φ hi SD Φ 3 0 P- SD H cr P1 3 SD o >< SD h-1 α Ω .
TJ tr β Φ SD SD (D P- 3 SD SD H Ω 3 CO 3 0 to φ P- Cfl φ U3 ,—. < P- tr rt >< rt i-1 3 Ω TJ O Ω 3 Ω Cfl SD tr H 3 vb "« CO φ Φ 3 O Ω SD P-
Φ β o tr 3 φ (D 3 O rt P- CO P- SD (D h-1 ^ P1 P- β μ- hj P- Hi tr 0 Ω 0 O H o (D o_ 3 o hi 3 0 cr α Ω Ω 3 rt • — Ω O SD CO o Φ l-J Ω 3
3 rt hi CO <: α 3 ιQ β Φ CO CO P- 0 O H • SD s β rt hi H (D h-1 ? TJ O •^
(D φ TJ P- μ- P- 3 hi * β α Ω CO SD 3 SD H Φ SD Φ Q 3 hi α hi Q Hi CΛ tr σ 3 (D β 3 (D 3 Ω β Ω ^ 0 Hi Φ rt O 3 r+ -~ β SD 0 o P- α μ-
3 β TJ (D Φ α 3 3 O -1 P- Φ CO Cfl tr 3 SD " φ SD CΛ β β • 3 >r £ Ω CO P- 3
Φ hi o rt P- 3 hi rt rt CO φ β O β rt CO h O SD H CO rt ω 3 Φ Ω 3 O rt 3 φ β o Ω ιQ hj Ω SD rt rf co 3 σ Ω M Φ n Ω o rt CO o ιQ TJ
P- tr CO P- 3 tr (D Φ O £ tr CO φ o o P- SD tr hi β Ω 3 a β P- o Φ CL P- 3 X ιQ tr SD o -1 Cfl 3 φ O 3 rt £ φ rt β rt rt hj
3 H 3 H β β O P- rt Φ P- SD ιQ H μ- O SD β rt Hi Φ μ- Φ 3 rt O p- O rt
3 iQ (D 3 hi Ω H 3 Ω CO P- P- β Cfl Ω CO * a o P- ιQ rt hj p μ-
CO o (D h-1 μ- SD ^ tr • Ω Ω CO tr O S P- H KQ β SD β β rt Ω β H CO H r~~ α Ω SD Ω Hi tr Φ β Hi Φ SD • \ 3 hi H O tr β
Φ (D Φ "< Φ rt CO 3 Ω Φ SD 0 CO SD hi 0 rt Ω. rt Φ β φ
Hi " β SD φ hi Ω hi SD ^ Cfl Ω H tr Hi rt > Cfl SD
SD rt o Ω • rt 0 P- CO Φ 0 0 tr hj rt O hj tr P- α Cfl α H φ tr < φ Ω CO 0 Φ Hi
or iron sulfate, which are necessary for growth. Finally, essential growth-promoting substances such- as amino acids and vitamins. may also be used in addition to the above- stated substances. Suitable precursors may furthermore be added to the culture medium. The stated feed substances may be added to the culture as a single batch or be fed appropriately during culturing.
Basic compounds, such as sodium hydroxide, potassium hydroxide, ammonia or ammonia water, or acidic compounds, such as phosphoric acid or sulfuric acid, are used appropriately to control the pH of the culture. Foaming may be controlled by using antifoaming agents such as fatty acid polyglycol esters for example. Plasmid stability may be maintained by the addition to the medium of suitable selectively acting substances, for example antibiotics.
Oxygen or oxygen-containing gas mixtures, such as air for example, are introduced into the culture in order to maintain aerobic conditions . The temperature of the culture is normally from 20 °C to 45°C and preferably from 25 °C to 40°C. The culture is continued until the maximum quantity of lysine has formed. This objective is normally achieved within 10 hours to 160 hours.
Analysis of L-lysine may be performed by anion exchange chromatography with subsequent ninhydrin derivatization, as described in Spackman et al. (Analytical Chemistry, 30, (1958), 1190).
The following microorganism has been deposited with Deutsche Sammlung fur Mikrorganismen und Zellkulturen (DSMZ, Braunschweig, Germany) in accordance with the Budapest Treaty:
• Corynebacterium glutamicum strain DSM5715/pJClcdsA as DSM 13252 The purpose of the process according to the invention is the fermentative production of amino acids, in particular L-lysine.
Key to the Figures :
Figure 1: Map of the plasmid pJClcdsA
The abbreviations and names are defined as follows..
0rf2,rep: plasmid-coded replication origin, C. glutamicum (from pHM1519)
cdsA: cdsA (phosphatidate cytidylyl transferase) gene from C. glutamicum ATCC13032
Kan: kanamycin resistance gene
Narl restriction site of the restriction enzyme Narl
Sail: restriction site of the restriction enzyme Sail
SgrAI restriction site of the restriction enzyme SgrAI
Bstll07 Restriction site of the restriction enzyme Bstll07
Nhel restriction site of the restriction enzyme Nhel
Xhol restriction site of the restriction enzyme Xhol
Clal restriction site of the restriction enzyme Clal
BstEII restriction site of the restriction enzyme BstEII EcoRI restriction site of the restriction enzyme EcoRI
Figure 2 :
Growth of C. glutamicum ATCC 13032 and ATCC 13032/pJCcdsA at 40°C.
OD: optical density Examples
The present invention is illustrated in greater detail by the following practical examples.
Example 1
Production of a genomic cosmid gene library from Corynebacterium glutamicum ATCC 13032
Chromosomal DNA from Corynebacterium glutamicum ATCC 13032 was isolated as described in Tauch et al., (1995, Plasmid 33:168-179) and partially cleaved with the restriction enzyme Sau3AI (Amersham Pharmacia, Freiburg, Germany, product description Sau3AI, code no. 27-0913-02). The DNA fragments were dephosphorylated with shrimp alkaline phosphatase (Roche Molecular Biochemicals, Mannheim, Germany, product description SAP, code no. 1758250) . The DNA of cosmid vector SuperCosl ( ahl et al. (1987) Proceedings of the National Academy of Sciences USA 84:2160-2164), purchased from Stratagene (La Jolla, USA, product description SuperCosl Cosmid Vector Kit, code no. 251301) was cleaved with the restriction enzyme Xbal
(Amersham Pharmacia, Freiburg, Germany, product description Xbal, Code no. 27-0948-02) and also dephosphorylated with shrimp alkaline phosphatase. The cosmid DNA was then cleaved with the restriction enzyme BamHI (Amersham Pharmacia, Freiburg, Germany, product description BamHI, code no. 27-0868-04) . Cosmid DNA treated in this manner was mixed with the treated ATCC 13032 DNA and the batch was treated with T4 DNA ligase (Amersham Pharmacia, Freiburg, Germany, product description T4 DNA Ligase, code no. 27- 0870-04) . The ligation mixture was then packed in phages using Gigapack II XL Packing Extracts (Stratagene, La Jolla, USA, product description Gigapack II XL Packing Extract, code no. 200217) . E. coli strain NM554 (Raleigh et al. 1988, Nucleic Acid Research 16:1563-1575) was infected by suspending the cells in 10 M MgS04 and mixing them with an aliquot of the phage suspension. The cosmid library was infected and titred as described in Sambrook et al. (1989, Molecular Cloning: A laboratory Manual, Cold Spring Harbor) , the cells being plated out on LB agar (Lennox, 1955, Virology, 1:190) with 100 mg/1 of ampicillin. After overnight incubation at 37 °C, individual recombinant clones were selected.
Example 2
Isolation and sequencing of the cdsA gene.
Cosmid DNA from an individual colony was isolated in accordance with the manufacturer's instructions using the Qiaprep Spin Miniprep Kit (Product No. 27106, Qiagen, Hilden, Germany) and partially cleaved with the restriction enzyme Sau3AI (Amersham Pharmacia, Freiburg, Germany, product description Sau3AI, code no. 27-0913-02) . The DNA fragments were dephosphorylated with shrimp alkaline phosphatase (Roche Molecular Biochemicals, Mannheim, Germany, product description SAP, code no. 1758250) . Once separated by gel electrophoresis, the cosmid fragments of a size of 1500 to 2000 bp were isolated using the QiaExII Gel Extraction Kit (product no. 20021, Qiagen, Hilden, Germany) . The DNA of the sequencing vector pZero-1 purchased from Invitrogen (Groningen, Netherlands, product description Zero Background Cloning Kit, product no. K2500- 01) was cleaved with the restriction enzyme BamHI (Amersham Pharmacia, Freiburg, Germany, product description BamHI, Product No. 27-0868-04) . Ligation of the cosmid fragments into the sequencing vector pZero-1 was performed as described by Sambrook et al. (1989, Molecular Cloning: A laboratory Manual, Cold Spring Harbor) , the DNA mixture being incubated overnight with T4 ligase (Pharmacia Biotech, Freiburg, Germany) . This ligation mixture was then electroporated into the E. coli strain DH5αMCR (Grant, 1990, Proceedings of the National Academy σf Sciences U.S.A., 87:4645-4649) (Tauch et al. 1994, FEMS Microbiol Letters, 123:343-7) and plated out onto LB agar (Lennox, 1955, Virology, 1:190) with 50 mg/1 of Zeocin. Plasmids of the recombinant clones were prepared using the Biorobot 9600 (product no. 900200, Qiagen, Hilden, Germany). Sequencing was performed using the dideoxy chain termination method according to Sanger et al. (1977, Proceedings of the National Academy of Sciences U.S.A., 74:5463-5467) as modified by Zimmermann et al. (1990, Nucleic Acids Research, 18:1067). The "RR dRhodamin Terminator Cycle Sequencing Kit" from PE Applied Biosystems (product no. '403044, Weiterstadt, Germany) was used. Separation by gel electrophoresis and analysis of the sequencing reaction was performed in a "Rotiphorese NF" acrylamide/bisacrylamide gel (29:1) (product no. A124.1, Roth, Karlsruhe, Germany) using the "ABI Prism 377" sequencer from PE Applied Biosystems (Weiterstadt, Germany) .
The resultant raw sequence data were then processed using the Staden software package (1986, Nucleic Acids Research, 14:217-231), version 97-0. The individual sequences of the pZero 1 derivatives were assembled into a cohesive contig. Computer-aided coding range analysis was performed using XNIP software (Staden, 1986, Nucleic Acids Research, 14:217-231). Further analysis was performed using the "BLAST search programs" (Altschul et al., 1997, Nucleic Acids Research, 25:3389-3402), against the non-redundant database of the "National Center for Biotechnology Information" (NCBI, Bethesda, MD, USA) .
The resultant nucleotide sequence is stated in SEQ ID no. 1. Analysis of the nucleotide sequence revealed an open reading frame of 891 base pairs, which was designated the cdsA gene. The cdsA gene codes for a protein of 297 amino acids .
Example 3
Cloning of the cdsA gene into vector pJCl
Chromosomal DNA from Corynebacterium glutamicum ATCC 13032 was isolated as described in Tauch et al., (1995, Plasmid 33:168-179) . A DNA fragment bearing the cdsA gene was amplified with the assistance of the polymerase chain reaction. The following primers were used for this purpose:
5"-CGC GGA TCC GTG GCC CAA GCT TTA CGA CGG ATA C-3*
5 -CGC GGA TCC GGC TCG CAA GGA AAA GGA ACT GAT-3
Both oligonucleotides bear the sequence for the cleavage site of the restriction enzyme BamHI (underlined nucleotides) . The stated primers were synthesized by the company MWG Biotech (Ebersberg, Germany) and the PCR reaction was thus performed in accordance with the standard PCR method of Innis et al., (PCR protocol. A guide to methods and applications, 1990, Academic Press). The primers allow the 1095 bp DNA fragment which bears the cdsA gene from Corynebacterium glutamicum to be amplified.
Once separated by gel electrophoresis, the PCR fragment was isolated from the agarose gel using the QiaExII Gel Extraction Kit (product no. 20021, Qiagen, Hilden, Germany) .
The PCR fragment obtained in this manner was completely cleaved with the restriction enzyme BamHI. The 1087 bp cdsA fragment was isolated from the agarose gel using the QiaExII Gel Extraction Kit (product no. 1087, Qiagen, Hilden, Germany) . The vector used was the E. coli - C. glutamicum shuttle vector pJCl (Cremer et al., 1990, Molecular and General Genetics 220: 478 - 480). This plasmid was also completely cleaved with the restriction enzyme BamHI and then dephosphorylated with shrimp alkaline phosphatase (Roche Diagnostics GmbH, Mannheim, Germany, product description SAP, product no. 1758250).
The cdsA fragment obtained in this manner was mixed with the prepared pJCl vector and the batch was treated with T4 DNA ligase (Amersham Pharmacia, Freiburg, Germany, product description T4 DNA Ligase, code no. 27-0870-04) . The ligation batch was then transformed into E. coli strain DH5α (Hanahan, in: DNA cloning. A practical approach. Vol. I. IRL-Press, Oxford, Washington DC, USA). Plasmid-bearing cells were selected by plating the transformation batch out onto LB agar (Lennox, 1995, Virology, 1:190) with 50 mg/1 of kanamycin. After overnight- incubation at 37 °C, individual recombinant clones were selected. Plasmid DNA was isolated from a transformant in accordance with the manufacturer's instructions using the Qiaprep Spin Miniprep Kit (product no. 27106, Qiagen, Hilden, Germany) and cleaved with the restriction enzyme BamHI in order to check the plasmid by subsequent agarose gel electrophoresis . The resultant plasmid was named pJClcdsA.
Example 4 :
Transformation of strain DSM5715 with plasmid pJClcdsA
Strain DSM5715 was then transformed with plasmid pJClcdsA using the electroporation method described by Liebl et al. (FEMS Microbiology Letters, 53:299-303 (1989)).
Transformant selection proceeded on LBHIS agar consisting of 18.5 g/1 of brain-heart infusion bouillon, 0.5 M sorbitol, 5 g/1 of Bacto tryptone, 2.5 g/1 of Bacto yeast extract, 5 g/1 of NaCl and 18 g/1 of Bacto agar, which had been supplemented with 25 mg/1 of kanamycin. Incubation was performed for 2 days at 33 °C.
Plasmid DNA was isolated from a transformant using the conventional methods (Peters-Wendisch et al., 1998,
Microbiology, 144, 915 - 927), cut with the restriction endonuclease BamHI, in order to check the plasmid by subsequent agarose gel elect-rophoresis . The resultant strain was named DSM5717/pJClcdsA and deposited with Deutsche Sammlung fur Mikrorganismen und Zellkulturen (DSMZ, Braunschweig, Germany) in accordance with the Budapest Treaty as DSM 13252.
Example 5:
Production of lysine
The C. glutamicum strain DSM5715/pJClcdsA obtained in Example 5 was cultured in a nutrient medium suitable for the production of L-lysine and the L-lysine content of the culture supernatant was determined.
To this end, the strain was initially incubated for 24 hours at 33°C on an agar plate with the appropriate antibiotic (brain/heart agar with kanamycin (50 mg/1) ) . Starting from this agar plate culture, a preculture was inoculated (10 ml of medium in a 100 ml Erlenmeyer flask) . The complete medium Cglll was used as the medium for this preculture.
Medium Cg III
NaCl 2.5 g/1
Bacto peptone 10 g/1 Bacto yeast extract 10 g/l
Glucose (separately autoclaved) 2% (w/v)
The pH value was adjusted to pH 7.4.
Kanamycin (25 mg/1) was added to this medium. The preculture was incubated for 16 hours at 33 °C on a shaker at 240 rpm. A main culture was inoculated from this preculture, such that the initial OD (660 nm) of the main culture was 0.1. Medium MM was used for the main culture.
Medium MM
CSL (Corn Steep Liquor) 5 g/1
MOPS (morpholinopropanesulfonic 20 g/1 acid)
Glucose (separately autoclaved) 50 g/1
(NH4)2S04 25 g/1
KH2P04 0.1 g/1
MgS04 * 7 H20 1.0 g/1
CaCl2 * 2 H20 10 mg/1
FeS04 * 7 H20 10 mg/1
MnS04 * H20 5.0 mg/1
Biotin (sterile-filtered) 0.3 mg/1
Thia ine * HC1 (sterile-filtered) 0.2 mg/1
L-Leucine 0.1 g/1
CaC03 25 g/1
CSL, MOPS and the salt solution were adjusted to pH 7 with ammonia water and autoclaved. The sterile substrate and vitamin solutions, together with the dry-autoclaved CaC03 are then added.
Culturing was performed in a volume of 10 ml in a 100 ml Erlenmeyer flask with flow spoilers. Kanamycin (25 mg/1) was added. Culturing was performed at 33°C and 80% atmospheric humidity. After 48 hours, the OD was determined at a measurement wavelength of 660 nm using a Biomek 1000 (Beckmann Instruments GmbH, Munich) . The quantity of lysine formed was determined using an amino acid analyzer from Eppendorf- BioTronik (Hamburg, Germany) by ion exchange chromatography and post-column derivatization- with ninhydrin detection.
Table 1 shows the result of the test.
Table 1
Figure imgf000027_0001
Example 6:
Improvement of growth characteristics
The plasmid pJCcdsA obtained in Example 3 was used to transform C. glutamicum strain ATCC 13032. This strain was transformed as described in Example 4 and checked as in Example 4 by restriction digestion and agarose gel electrophoresis. The strain resultant [sic] ATCC 13032/pJCcdsA was cultured in a nutrient medium suitable for determining growth and growth was determined at various temperatures .
To this end, the strain was initially incubated for 24 hours at 30 °C as described in Example 5 on an agar plate with the appropriate antibiotic (brain/heart agar with kanamycin (5 mg/1) ) . Starting from this agar plate culture, a preculture was inoculated (10 ml of medium in a 100 ml Erlenmeyer flask) . The complete medium Cglll stated in Example 5 was used as the medium for this preculture. Kanamycin (25 mg/1) was added to this medium. The preculture was incubated for 16 hours at 30°C on a shaker at 240 rpm. A main culture was inoculated from this preculture, such that the initial OD (600 nm) of the main culture was 0.7. Medium MM was used for the main culture.
Medium MM
MOPS (morpholinopropanesulfonic 42 g/1 acid)
Glucose (separately autoclaved) 40 g/1
(NH4)2S04 20 g/1
KH2P04 1.0 g/1
K2HP04 1.0 g/1
MgS04 * 7 H20 0.25 g/1
CaCl2 * 2 H20 10 mg/1
FeS0 * 7 H20 10 mg/1
MnS04 * H20 10 mg/1
ZnS04 * H20 1 mg/1
CuS04 " 0.2 mg/1
NiCl2 * 6 H20 0.02 mg/1
Biotin (sterile-filtered) 0.2 mg/1
Protocatechuic acid 30 mg/1 (sterile-filtered) MOPS and the salt solution were adjusted to pH 7 with ammonia water and autoclaved. The sterile substrate and vitamin solutions were then added.
Culturing was performed in a volume of 60 ml in a 500 ml Erlenmeyer flask with flow spoilers. Kanamycin (25 mg/1) was added. Culturing was performed at 40°C. OD was determined at a measurement wavelength of 600 nm using an Ultrospec 3000 (Pharmacia Biotech, Uppsala, Sweden) . Table 2 shows the result of the test.

Claims

Patent Claims
1. A genetically modified coryneform bacterium, wherein the cdsA gene thereof, which codes for phosphatidate cytidylyl transferase, is amplified.
2. The genetically modified coryneform bacterium as claimed in claim 1, wherein the starting bacterium (wild type) is selected from the group Corynebacterium glutamicum (ATCC13032) , Corynebacterium acetoglutamicum (ATCC15806) , Corynebacterium acetoacidophilum (ATCC13870) , Corynebacterium thermoaminogenes (FERM BP-1539) , Corynebacterium melassecola (ATCC17965) , Brevibacterium flavum (ATCC14067), Brevibacterium lactofermentum (ATCC13869) and Brevibacterium divaricatum (ATCC14020) , or is selected from the group Corynebacterium glutamicum FERM-P 1709, Brevibacterium flavum . FERM-P 1708, Brevibacterium lactofermentum FERM-P 1712, Corynebacterium glutamicum FERM-P 6463, Corynebacterium glutamicum FERM-P 6464 and Corynebacterium glutamicum DSM5715.
3. The genetically modified coryneform bacterium as claimed in claim 1, wherein the cdsA gene is amplified by overexpressing the gene, in particular by increasing the copy number of the gene, by selecting a strong promoter or a regulation region upstream from the reading frame, by mutating the promoter, the regulation region or the ribosome-binding site, by incorporating a suitable expression cassette upstream from the structural gene or by incorporating inducible promoters, by extending the lifetime of the corresponding mRNA, by reducing degradation of the expressed proteins, or by combining two or more of these possibilities.
4. The genetically modified coryneform bacterium as claimed in one of claims 1 to 3, wherein the strain is transformed with a plasmid vector and the plasmid vector bears the nucleotide sequence which codes for the cdsA gene.
5. The genetically modified coryneform bacterium as claimed in one of claims 1 to 4, wherein it corresponds genotypically to the strain Corynebacterium glutamicum DSM 13252.
6. An isolated polynucleotide from coryneform bacteria containing a polynucleotide sequence selected from the group
a) polynucleotide which is at least 70% homologous to a polynucleotide which codes for a polypeptide which comprises or consists of the amino acid sequence of SEQ ID no. 2,
b) polynucleotide which codes for a polypeptide which comprises an amino acid sequence which is at least 70% homologous to the amino acid sequence of SEQ ID no. 2,
c ) polynucleotide which is complementary to the polynucleotides of a) or b) and
d) polynucleotide containing at least 15 successive nucleotides of the polynucleotide sequence of a) , b) or c ) .
7. The polynucleotide as claimed in claim 6, wherein the polynucleotide is a preferably recombinant DNA replicable in coryneform bacteria.
8. The polynucleotide as claimed in claim 6, wherein the polynucleotide is an RNA.
9. The replicable DNA as claimed in claim 7, containing
(i) the nucleotide sequence shown in SEQ ID no. 1, or
(ϋ) at least one sequence which corresponds to the sequence (i) within the degeneration range of the genetic code, or
(iii) at least one sequence which hybridizes with the complementary sequence to sequence (i) or (ii) and optionally
(iv) functionally neutral mutations in (i) which give rise to homologous amino acids.
10. The polynucleotide sequence as claimed in claim 7, 8 or 9, which codes for a polypeptide which comprises the amino acid sequence SEQ ID no. 2.
11. A process for the fermentative production of L-amino acids, w h e r e i n , the following steps are performed: a) fermentation of L-amino acid producing coryneform bacteria in which at least the cdsA gene or nucleotide sequences coding therefor is/are amplified, in particular overexpressed, b) accumulation of the L-amino acid in the medium or in the cells of the bacteria and c) isolation of the L-amino acid.
12. The process as claimed in claim 11, w e r e i n , a strain as claimed in one of claims 1 to 5 is used.
13. The process as claimed in claim 11 or 12, w h e r e i n , additionally further genes, which code for a protein of the biosynthetic pathway of the desired L-amino acid, are amplified in the bacteria.
14. The process as claimed in one of claims 11 to 13, w h e r e i n , metabolic pathways which reduce the formation of the desired amino acid are at least partially suppressed in the bacteria.
15. The process as claimed in one of claims 11 to 14, w h e r e i n , the amino acid produced is L-lysine.
16. The process as claimed in one of claims 11 to 15, h e r e i n , bacteria are fermented for the production of lysine in which simultaneously [sic] one or more of the genes selected from the group
a) the dapA gene which codes for dihydropicolinate synthase,
b) the dapE gene which codes for succinyldiamino pimelate desuccinylase,
c) the lysC gene which codes for a feed back resistant aspartate kinase,
d) the tpi gene which codes for triosephosphate isomerase,
e) the gap gene which codes for glyceraldehyde 3-phosphate dehydrogenase,
f) the pgk gene which codes for 3-phosphoglycerate kinase, g) the pyc gene which codes for pyruvate carboxylase,
h) the qo gene which codes for malate : quinone oxidoreductase,
i) the lysE gene which codes for lysine export,
is/are simultaneously amplified, in particular overexpressed or amplified [sic] .
17. The process as claimed in one of claims 12 to 17, w h e r e i n , bacteria are fermented for the production of L-lysine in which one or more genes selected from the group
a) the pck gene which codes for phosphoenolpyruvate carboxy inase,
b) pgi gene which codes for glucose 6-phosphate isomerase,
c) the poxB gene which codes for pyruvate oxidase
is/are simultaneously attenuated.
18. A use of polynucleotide sequences or parts thereof as claimed in claim 6 as primers for the production of DNA of genes which code for phosphatidate cytidylyl transferase by the polymerase chain reaction.
19. A use of polynucleotide sequences as claimed in claim 6 as hybridization probes for the isolation of cDNA or genes which exhibit elevated homology with the sequence of the cdsA gene.
PCT/EP2001/003704 2000-05-04 2001-03-31 Nucleotides sequences coding for the cdsa gene WO2001083765A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01933786A EP1278861A2 (en) 2000-05-04 2001-03-31 Nucleotide sequences coding for the cdsa gene
KR1020027014698A KR20020097245A (en) 2000-05-04 2001-03-31 Nucleotides sequences coding for the cdsA gene
AU2001260174A AU2001260174A1 (en) 2000-05-04 2001-03-31 Novel nucleotide sequences coding for the cdsa gene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10021828.8 2000-05-04
DE10021828A DE10021828A1 (en) 2000-05-04 2000-05-04 New nucleotide sequences coding for the cdsA gene

Publications (2)

Publication Number Publication Date
WO2001083765A2 true WO2001083765A2 (en) 2001-11-08
WO2001083765A3 WO2001083765A3 (en) 2002-04-04

Family

ID=7640835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/003704 WO2001083765A2 (en) 2000-05-04 2001-03-31 Nucleotides sequences coding for the cdsa gene

Country Status (5)

Country Link
EP (1) EP1278861A2 (en)
KR (1) KR20020097245A (en)
AU (1) AU2001260174A1 (en)
DE (1) DE10021828A1 (en)
WO (1) WO2001083765A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100653742B1 (en) * 2004-12-30 2006-12-05 씨제이 주식회사 -- Novel L-lysine-inducible promoter
KR100973056B1 (en) * 2009-09-28 2010-07-29 정충호 Cleaning apparatus

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0771879A1 (en) * 1994-06-14 1997-05-07 Ajinomoto Co., Inc. $g(a)-KETOGLUTARIC DEHYDROGENASE GENE
WO2001000805A2 (en) * 1999-06-25 2001-01-04 Basf Aktiengesellschaft Corynebacterium glutamicum genes encoding proteins involved in membrane synthesis and membrane transport
WO2001000843A2 (en) * 1999-06-25 2001-01-04 Basf Aktiengesellschaft Corynebacterium glutamicum genes encoding metabolic pathway proteins
EP1108790A2 (en) * 1999-12-16 2001-06-20 Kyowa Hakko Kogyo Co., Ltd. Novel polynucleotides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4130867A1 (en) * 1991-09-17 1993-03-18 Degussa PROCESS FOR THE FERMENTATIVE MANUFACTURE OF AMINO ACIDS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0771879A1 (en) * 1994-06-14 1997-05-07 Ajinomoto Co., Inc. $g(a)-KETOGLUTARIC DEHYDROGENASE GENE
WO2001000805A2 (en) * 1999-06-25 2001-01-04 Basf Aktiengesellschaft Corynebacterium glutamicum genes encoding proteins involved in membrane synthesis and membrane transport
WO2001000843A2 (en) * 1999-06-25 2001-01-04 Basf Aktiengesellschaft Corynebacterium glutamicum genes encoding metabolic pathway proteins
EP1108790A2 (en) * 1999-12-16 2001-06-20 Kyowa Hakko Kogyo Co., Ltd. Novel polynucleotides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EGGELING L. AND SAHM H.: "L-Glutamate and L-Lysine: traditional products with impetuous developments" APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, vol. 52, August 1999 (1999-08), pages 146-153, XP000979507 ISSN: 0175-7598 *
See also references of EP1278861A2 *

Also Published As

Publication number Publication date
KR20020097245A (en) 2002-12-31
AU2001260174A1 (en) 2001-11-12
EP1278861A2 (en) 2003-01-29
WO2001083765A3 (en) 2002-04-04
DE10021828A1 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
US7118904B2 (en) Nucleotide sequences which code for the eno gene
MXPA01002860A (en) Nucleotide sequences encoding the dapc gene and process for the production of l-lysine.
EP1287143B1 (en) Corynebacterium glutamicum nucleotide sequences coding for the glbo gene
KR20010086331A (en) New nucleotide sequences coding for the ptsH gene
US7205131B2 (en) Process for the preparation of L-amino acids via overexpression of the PTSH gene
US6913910B2 (en) Nucleotide sequences coding for the glk-gene
US20040005675A9 (en) Nucleotide sequences encoding the ptsH gene
US6949374B2 (en) FadD15 gene of Corynebacterium glutamicum, encoding an acyl-CoA synthase polypeptide
US6830921B2 (en) Nucleotide sequences which code for the ACP gene
WO2001083765A2 (en) Nucleotides sequences coding for the cdsa gene
US20070054379A1 (en) Nucleotide sequences which encode the pfk gene
CA2324485A1 (en) Novel nucleotide sequences coding for the pfka gene
EP1278860B1 (en) Nucleotide sequences which code for the cma gene
US6987015B1 (en) Nucleotide sequences encoding the pfkA gene
US6562607B2 (en) Nucleotide sequences coding for the cls gene
US6638753B2 (en) Nucleotide sequences which code for the cma gene
US20040092710A1 (en) Nucleotide sequences coding for the cdsA gene
US20020155555A1 (en) Nucleotide sequences which code for the pgsA2 gene
US20020034794A1 (en) Nucleotide sequences which encode the gpsA gene
WO2002002779A2 (en) Nucleotide sequences which encode the plsc protein
EP1278857A1 (en) Nucleotide sequences which code for the fadd15 gene
WO2002002777A2 (en) Gpsa gene from corynebaxteria and use thereof in synthesis of l-amino acids
KR20020097244A (en) New nucleotide sequences which code for the pgsA2 gene
EP1278862A2 (en) Nucleotide sequences coding for the cls gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001933786

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020027014698

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1020027014698

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001933786

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001933786

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP